An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors

Personalized mRNA vaccine shows promise in preventing melanoma recurrence when combined with immunotherapy

An 80-year-old melanoma patient, Connie Franciosi, participated in a clinical trial testing an mRNA cancer vaccine (mRNA-4157/V940) combined

Personalized glioblastoma vaccine shows safety and survival promise in phase 1 trial

A phase 1 clinical trial at Siteman Cancer Center found that a personalized vaccine for glioblastoma, an aggressive brain cancer, is safe an

Personalized mRNA vaccine from Moderna and Merck halves melanoma recurrence risk over five years

A personalized mRNA vaccine developed by Moderna and Merck has shown in new clinical trial results that it halves the risk of melanoma retur

Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up

Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy.

Personalized mRNA vaccine combined with Keytruda shows 49% reduction in melanoma recurrence risk

An 80-year-old melanoma patient, Connie Franciosi, participated in a clinical trial testing an mRNA cancer vaccine (mRNA-4157/V940) combined

Personalized mRNA vaccine combined with Keytruda shows 49% reduction in melanoma recurrence risk

An 80-year-old melanoma patient, Connie Franciosi, participated in a clinical trial testing an mRNA cancer vaccine (mRNA-4157/V940) combined

Programming the immunological properties of mRNA vaccines for cancer